appeared in the *Economic Times* on 27th January, 1989, under the heading of DPCO impact favourable;

(b) if so, what are the basis on which the control measured and how Chairman BICP have come to the conclusion that under DPCO, 1987, the span of price control has been reduced from 77 per cent to 73 per cent;

(c) what are the basis and details of data on which he drew the conclusion that price control has become less cumbersome and at the same time more effective;

(d) whether it is a fact that the methodology of price control remains the same and producer has to sell out more to sell his product *vis-a-vis* small scale; and

(e) whether it is a fact that the worst sufferer is the consumer?

THE MINISTER OF INDUSTRY (SHRI J. VENGAL RAO): (a) Yes, Sir.

(b) The required details, to the extent available, will be collected and laid on the Table of the House.

(c) It was made in the context of reduction in the number of drugs under DPCO, 1987 from DPCO, 1979.

(d) The number of categories under control have been reduced from 3 to 2 improving the methodology.

(e) No, Sir.

Drugs and Formulations for Whole-sale Index

620 CHOWDHARY RAM SEWAK: Will the Minister of INDUSTRY be pleased to state:

(a) what are the names of the bulk drugs and formulations in the basket of wholesale price index and when were they included;

(b) whether there is any proposal to review the basket and by when the basket would be reviewed;

(c) what was the wholesale price index of bulk drugs and formulations as in August, 1987, December, 1987 and December, 1988; and

(d) what is the weightage assigned to each bulk drug and formulations for the purpose of compiling the index?

THE MINISTER OF INDUSTRY (SHRI J. VENGAL RAO): (a) to (d) The required details to the extent available, will be collected and laid on the Table of the House.

Concentration of Formulation Market

621. CHOWDHARY RAM SEWAK: Will the Minister of INDUSTRY be pleased to state:

(a) whether the criterion of very high concentration of formulation market is a new criterion evolved by the Kelkar Committee;

(b) whether it is a fact that this criterion was not used in the initial report;

(c) if so, how drugs like Triprolidine, Polymixin B Sulphate, Flucinolone, Nandrolone Phenyl Propionate and Nandrolone Decanoate were omitted from the list proposed for price control;

(d) what is the percentage control in the market share that has been kept in view to determine the degree of concentration; and

(e) what are the names of drugs recommended for price control based on new criteria in the supplementary report?

THE MINISTER OF INDUSTRY (SHRI J. VENGAL RAO): (a) to (e) The required details, to the extent available, will be collected and laid on the Table of the House.

Filling wrong affidavits about Baralgon Ketone

622 SHRI ALADI ARUNA *alias* V. ARUNACHALAM. Will the Minister of INDUSTRY be pleased to refer to the answer to Starred Question 239 given in